38 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 38 of 38 clinical reviews.
A physician-level review of alprostadil pharmacology, efficacy, and safety in patients with autoimmune conditions including lupus, rheumatoid arthritis, Sjogren syndrome, and vasculitis. Includes dosing, contraindications, and clinical decision guidance.
A clinician-level review of the available pharmacovigilance data, mechanistic arguments, and primary literature on whether alprostadil (Caverject, MUSE) carries a meaningful cancer risk signal for men using it to treat erectile dysfunction.
A clinician-level review of alprostadil's long-term cardiovascular effects, hemodynamic profile, safety data, and prescribing considerations for men with erectile dysfunction and concurrent cardiac disease.
An evidence-based guide to every clinically significant drug interaction with alprostadil, covering antihypertensives, anticoagulants, vasoactive agents, PDE5 inhibitors, and more. Includes dosing context, mechanism explanations, and management strategies.
Compare alprostadil injection and suppository costs against PDE5 inhibitors, trimix, and penile implants. Includes per-dose pricing, efficacy data, and insurance coverage analysis.
Complete clinical dosing guide for alprostadil intracavernosal injection and urethral suppository in older adults ages 50, 64, including titration protocols, cardiovascular considerations, and polypharmacy interactions.
Evidence-based guide to alprostadil dosing for erectile dysfunction in patients with liver disease. Covers pharmacokinetics, dose adjustments, monitoring, and safety across Child-Pugh classes.
A guide to alprostadil dosing in chronic kidney disease and renal impairment, covering mechanism, intracavernosal vs. Urethral formulations, titration protocols, and safety monitoring.
A clinician-level review of alprostadil's emerging delivery systems, combination approaches, and pipeline agents targeting refractory erectile dysfunction beyond the current intracavernosal and intraurethral formulations.
Evidence-based guide to alprostadil dosing in men aged 65 and older, covering intracavernosal injection and intraurethral suppository titration, renal adjustment, fall-risk management, and AUA guideline recommendations.
A guide to the dermatologic effects of alprostadil injection and suppository therapy, including hair changes, skin reactions, and clinical management strategies.
A physician-level review of whether alprostadil (Caverject, MUSE) affects liver function, including pharmacokinetic data, clinical trial evidence, and dosing guidance for patients with hepatic impairment.
A physician-level explanation of how alprostadil (prostaglandin E1) produces erections, from EP receptor binding through smooth-muscle relaxation, with clinical trial data and FDA-cited evidence.
A physician-level review of how alprostadil is absorbed, distributed, metabolized, and eliminated, plus its documented effects on local and systemic energy expenditure. Includes dosing, pharmacokinetics, and clinical trial data.
Evidence-based monitoring guide for alprostadil (Caverject, MUSE) in adults aged 30 to 49. Covers injection-site checks, penile fibrosis screening, blood pressure tracking, dose titration, and when to schedule follow-up visits.
A clinician-grade review of alprostadil off-label applications, from penile rehabilitation and trimix therapy to Raynaud's phenomenon and female sexual dysfunction, with trial-level evidence grading.
What happens when too much alprostadil is injected or inserted, how to recognize prolonged erection and systemic toxicity, and the step-by-step emergency protocol physicians follow.
Complete clinical guide to alprostadil dosing in pediatric patients under 12, covering FDA-approved indications, weight-based prostaglandin E1 protocols for congenital heart disease, and off-label considerations with primary-source citations.
A detailed clinical review of alprostadil safety in pediatric patients under 12, covering FDA labeling, congenital heart disease uses, dosing considerations, adverse effects, and monitoring protocols.
A physician-level review of how genetic variation in prostaglandin receptors, metabolizing enzymes, and vascular signaling pathways shapes alprostadil response, dosing, and side-effect risk in men with erectile dysfunction.
A deep dive into alprostadil pharmacokinetics covering absorption, distribution, metabolism, excretion, and mechanism of action for Caverject and MUSE formulations.
A clinician-level guide to diagnosing and correcting alprostadil plateau and non-response in men with refractory erectile dysfunction, including dose optimization, combination strategies, and when to escalate care.
A clinician-level guide to managing alprostadil hold windows before surgery, covering pharmacokinetics, priapism risk, anesthesia interactions, and evidence-based perioperative protocols.
Does stopping alprostadil cause rebound ED or withdrawal? An evidence-based guide covering what happens physiologically when you discontinue Caverject injections or MUSE suppositories, with primary-literature citations.
A clinical guide to alprostadil regulatory approvals, brand availability, and prescribing frameworks across the United States, European Union, Canada, and the United Kingdom.
A guide to alprostadil safety in men aged 30 to 49, covering injection-site reactions, priapism risk, contraindications, dosing protocols, and how intracavernosal versus intraurethral delivery compare on the safety profile.
A guide to alprostadil safety for men aged 18, 29, covering injection technique, priapism risk, fertility considerations, dosing, and how to integrate on-demand therapy into an active young-adult lifestyle.
A physician-level review of alprostadil safety signals, FDA regulatory actions, post-market surveillance data, and clinical risk management for Caverject and MUSE.
A clinician-level guide to how temperature, humidity, travel, and seasonal vascular changes affect alprostadil (Caverject/MUSE) storage, dosing, and efficacy in men with refractory erectile dysfunction.
Step-by-step alprostadil intracavernosal injection and MUSE urethral suppository technique, with dosing, mechanism, safety data from Linet et al. (NEJM 1996), and guidance for men with refractory erectile dysfunction.
Evidence-based guide to storing alprostadil intracavernosal injections and MUSE urethral suppositories, including temperature requirements, reconstituted solution stability, and shelf-life data from FDA labeling and primary literature.
Evidence-based alprostadil dosing guide for young adults aged 18-29, covering Caverject intracavernosal injection and MUSE urethral suppository titration, safety monitoring, and fertility considerations.
A clinical history of alprostadil for erectile dysfunction, from prostaglandin E1 discovery through FDA approval of Caverject and MUSE, with mechanism of action and trial evidence.
A guide to discontinuing alprostadil injections and urethral suppositories, covering taper strategies, rebound physiology, transition to oral PDE5 inhibitors, and when stopping is the right clinical move.
A complete guide to Aetna (CVS Health) coverage of alprostadil (Caverject/MUSE) for erectile dysfunction, including prior authorization criteria, step therapy requirements, formulary tier, and appeal strategies.
A clinical guide to BCBS Federated coverage of alprostadil (Caverject/MUSE) for erectile dysfunction, including prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A state-by-state breakdown of Medicaid coverage for alprostadil injections and suppositories, including prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A detailed guide to UnitedHealthcare coverage for alprostadil (Caverject and MUSE), including formulary tier, prior authorization criteria, step therapy rules, appeal pathways, and cost-saving options for men with erectile dysfunction.